Traders should monitor near-term sales uptake and gross margin trends, as limited-competition generics typically offer strong profitability. This approval adds to ANI’s track record of successful ANDA approvals and may support valuation re-rating if commercial execution continues.
Price Chart
Executive Summary
ANI Pharmaceuticals announced FDA approval and immediate launch of Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg, the generic version of Monoket®, reinforcing its generics pipeline and R&D execution. The product targets a limited-competition market, supporting near-term revenue diversification.
Key Facts
- FDA approved ANI's Abbreviated New Drug Application (ANDA) for Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg.
- Product launched immediately as a generic version of Monoket®.
- Indication is for cardiovascular conditions, with limited competition expected.
- Strengthens ANI’s Generics business and R&D track record.
Financial Impact
Moderate revenue contribution expected; exact sales figures not disclosed but positioned as part of steady product launch cadence.
Risk Factors
- Uncertainty around market adoption and competition despite 'limited-competition' claim.
- Supply chain or manufacturing delays could hinder revenue realization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269952 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $72.11 $77.91 | ▲ +8.04% | ▲ +7.23% | $71.97 (−0.19%) |
Sep 1, 2026 4w ago | Insider Cluster | $73.06 $71.46 | ▼ −2.19% | ▼ −1.23% | $71.97 (−1.49%) |
Aug 24, 2026 5w ago | 8-K | $74.17 $73.25 | ▼ −1.24% | ▼ −1.71% | $71.97 (−2.97%) |
Aug 13, 2026 7w ago | Insider Cluster | $74.77 $77.32 | ▲ +3.41% | ▲ +5.37% | $71.97 (−3.74%) |
Aug 7, 2026 8w ago | 8-K | $78.25 $76.54 | ▼ −2.19% | ▼ −2.58% | $71.97 (−8.03%) |
Jul 16, 2026 11w ago | Court Ruling | $81.92 $78.53 | ▼ −4.14% | ▼ −2.47% | $71.97 (−12.15%) |
Jul 13, 2026 11w ago | Press Release | $81.08 $79.20 | ▼ −2.32% | ▼ −1.53% | $71.97 (−11.24%) |
Jun 15, 2026 15w ago | Insider Cluster | $83.00 $82.94 | ▼ −0.07% | ▲ +2.16% | $71.97 (−13.29%) |
Jun 11, 2026 16w ago | Insider Cluster | $81.65 $80.52 | ▼ −1.38% | ▼ −1.82% | $71.97 (−11.86%) |
May 21, 2026 19w ago | 8-K | $82.72 $76.71 | ▼ −7.27% | ▼ −8.92% | $71.97 (−13.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access